New Horizons in Radioligand Therapy: 161Tb-PSMA-617 in Advanced mCRPC
Rosar F, Maus S, Schaefer-Schuler A, Burgard C, Khreish F, Ezziddin S (2023)
Publication Type: Journal article
Publication year: 2023
Journal
Book Volume: 48
Pages Range: 433-434
Journal Issue: 5
DOI: 10.1097/RLU.0000000000004589
Abstract
An 85-year-old man with advanced metastatic castration-resistant prostate cancer and progression after 8 cycles of 177Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) received 1 cycle of 161Tb-PSMA RLT. This one administration of 6.5 GBq 161Tb-PSMA-617 resulted in impressive partial remission with a PSA decline by 53.4% (from 474 to 221 ng/mL) and a concomitant decrease in tumor burden on PSMA PET/CT imaging. The presented case provides stunning initial evidence of the therapeutic potential of 161Tb-PSMA RLT in metastatic castration-resistant prostate cancer, even in patients progressing after extensive 177Lu-based RLT. 161Tb-labeled PSMA ligands may thus offer a promising alternative to standard PSMA RLT.
Involved external institutions
Germany (DE)How to cite
APA:
Rosar, F., Maus, S., Schaefer-Schuler, A., Burgard, C., Khreish, F., & Ezziddin, S. (2023). New Horizons in Radioligand Therapy: 161Tb-PSMA-617 in Advanced mCRPC. Clinical Nuclear Medicine, 48(5), 433-434. https://doi.org/10.1097/RLU.0000000000004589
MLA:
Rosar, Florian, et al. "New Horizons in Radioligand Therapy: 161Tb-PSMA-617 in Advanced mCRPC." Clinical Nuclear Medicine 48.5 (2023): 433-434.
BibTeX: Download